| First Author | Zhu J | Year | 2007 |
| Journal | J Immunol | Volume | 178 |
| Issue | 6 | Pages | 3505-10 |
| PubMed ID | 17339445 | Mgi Jnum | J:144287 |
| Mgi Id | MGI:3830591 | Doi | 10.4049/jimmunol.178.6.3505 |
| Citation | Zhu J, et al. (2007) Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus. J Immunol 178(6):3505-10 |
| abstractText | Recombinant adenoviruses have been used as vehicles for gene therapy as well as vaccination against infectious diseases and cancer. Efficient activation of host B cell response to adenoviral vectors that leads to the generation of protective, neutralizing Ab, represents a major barrier for gene therapy, but an attractive feature for vaccine development. What regulate(s) potent B cell response to adenoviral vectors remains incompletely defined. In this study, we showed that type I IFNs induced upon adenoviral infection are critical for multiple stages of adaptive B cell response to adenovirus including early B cell activation, germinal center formation, Ig isotype switching as well as plasma cell differentiation. We further demonstrated that although type I IFN signaling on dendritic cells was important for the production of virus-specific IgM, the generation of protective neutralizing Ab critically depended on type I IFN signaling on both CD4 T and B cells. The results may suggest potential strategies for improving adenovirus-mediated gene therapy in vivo and/or the design of effective vaccines for cancer and infectious diseases. |
